Behavioural and medical predictors of bacterial vaginosis recurrence among female sex workers: longitudinal analysis from a randomized controlled trial

BMC Infectious Diseases

Michel Alary⁵  Suniti Solomon¹  Florence Mirembe⁶  Marissa Becker⁴  Tania Crucitti²  Jennifer Deese³  Lut Van Damme³  Fernand A Guédou⁵ 

[1] Y.R. Gaitonde Center for AIDS Research and Education, Chennai, India;Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium;FHI360, Durham, NC, USA;Centre for Global Public Health, University of Manitoba, Winnipeg, Canada;URESP, Centre de recherche FQRS du CHU de Québec, Département de Médecine Sociale et Préventive, Université Laval, Québec, Canada;Makerere University College of Health Sciences, Kampala, Uganda

关键词: Microbicide trial;    Female sex workers;    Predictors;    Recurrence;    Bacterial vaginosis;   

Others  :  1148504
DOI  :  10.1186/1471-2334-13-208

 received in 2013-01-04, accepted in 2013-05-04,  发布年份 2013

【 摘 要 】

Background

Data on risk factors of recurrent bacterial vaginosis (RBV) are still scarce. We used data from female sex workers (FSW) participating in a randomized controlled microbicide trial to examine predictors of BV recurrence.

Methods

Trial’s participants with at least an episode of BV which was treated and/or followed by a negative BV result and at least one subsequent visit offering BV testing were included in the analysis. Behavioural and medical data were collected monthly while laboratory testing for STI and genital tract infections were performed quarterly. The Andersen-Gill proportional hazards model was used to determine predictors of BV recurrence both in bivariate and multivariate analyses.

Results

440 women were included and the incidence rate for RBV was 20.8 recurrences/100 person-months (95% confidence interval (CI) =18.1–23.4). In the multivariate analysis controlling for the study site, recent vaginal cleansing as reported at baseline with adjusted hazard-ratio (aHR)=1.30, 95% CI = 1.02-1.64 increased the risk of BV recurrence, whereas consistent condom use (CCU) with the primary partner (aHR=0.68, 95% CI=0.49-0.93) and vaginal candidiasis (aHR=0.70, 95% CI=0.53-0.93), both treated as time-dependent variables, were associated with decreased risk of RBV.

Conclusion

This study confirms the importance of counselling high-risk women with RBV about the adverse effects of vaginal cleansing and the protective effects of condom use with all types of partners for the prevention of sexually transmitted infections, including BV. More prospective studies on risk factors of BV recurrence are warranted.

Trial registration

Trial registration:NCT00153777

【 授权许可】

   
2013 Guédou et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Koumans EH, Sternberg M, Bruce C, McQuillan G, Kendrick J, Sutton M, Markowitz LE: The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007, 34:864-9.
• [2]Sewankambo N, Gray RH, Wawer MJ, Paxton L, McNaim D, Wabwire-Mangen F, Serwadda D, Li C, Kiwanuka N, Hillier SL, Rabe L, Gaydos CA, Quinn TC, Konde-Lule J: HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997, 350:546-50.
• [3]Johnson LF, Coetzee DJ, Dorrington RE: Sentinel surveillance of sexually transmitted infections in South Africa: a review. Sex Transm Infect 2005, 81:287-93.
• [4]Eckert LO, Moore DE, Patton DL, Agnew KJ, Eschenbach DA: Relationship of vaginal bacteria and inflammation with conception and early pregnancy loss following in-vitro fertilization. Infect Dis Obstet Gynecol 2003, 11:11-7.
• [5]Joesoef MR, Wiknjosastro G, Norojono W, Sumampouw H, Linnan M, Hansell MJ, Hillis SE, Lewis J: Coinfection with chlamydia and gonorrhoea among pregnant women and bacterial vaginosis. Int J STD AIDS 1996, 7:61-4.
• [6]Gallo MF, Macaluso M, Warner L, Fleenor ME, Hook EW 3rd, Brill I, Weaver MA: Bacterial vaginosis, gonorrhea, and chlamydial infection among women attending a sexually transmitted disease clinic: a longitudinal analysis of possible causal links. Ann Epidemiol 2012, 22:213-20.
• [7]Cohen CR, Lingappa JR, Baeten JM, Ngayo MO, Spiegel CA, Hong T, Donnell D, Celum C, Kapiga S, Delany S, Bukusi EA: Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among african couples. PLoS Med 2012, 9:e1001251.
• [8]McGregor JA, French JI, Parker R, Draper D, Patterson E, Jones W, Thorsgard K, McFee J: Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation. Am J Obstet Gynecol 1995, 173:157-67.
• [9]van de Wijgert JH, Morrison CS, Brown J, Kwok C, Van Der Pol B, Chipato T, Byamugisha JK, Padian N, Salata RA: Disentangling contributions of reproductive tract infections to HIV acquisition in African Women. Sex Transm Dis 2009, 36:357-64.
• [10]Myer L, Denny L, Telerant R, Souza M, Wright TC Jr, Kuhn L: Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case–control study. J Infect Dis 2005, 192:1372-80.
• [11]Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, MacDonald KS, Maclean IW, Bwayo JJ, Temmerman M, Ronald AR, Moses S, Kibera HIV Study Group: Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004, 291:2555-62.
• [12]McClelland RS, Richardson BA, Hassan WM, Chohan V, Lavreys L, Mandaliya K, Kiarie J, Jaoko W, Ndinya-Achola JO, Baeten JM, Kurth AE, Holmes KK: Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis 2008, 197:1361-8.
• [13]Schwebke JR, Desmond R: A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol 2007, 196(517):e1-6.
• [14]Sobel JD, Ferris D, Schwebke J, Nyirjesy P, Wiesenfeld HC, Peipert J, Soper D, Ohmit SE, Hillier SL: Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol 2006, 194:1283-9.
• [15]Meltzer MC, Desmond RA, Schwebke JR: Association of Mobiluncus curtisii with recurrence of bacterial vaginosis. Sex Transm Dis 2008, 35:611-3.
• [16]Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D, CS Study Group: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008, 359:463-72.
• [17]Nugent RP, Krohn MA, Hillier SL: Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991, 29:297-301.
• [18]British Association for Sexual Health and HIV CEG: National guideline for the management of bacterial vaginosis. 2006. Available from: http://www.bashh.org/documents/62/62.pdf webcite. Accessed 17 December 2012
• [19]Andersen PK, Gill RD: Cox's regression model for counting processes:a large sample study. Ann Stat 1982, 10:1100-20.
• [20]Bradshaw CS, Pirotta M, De Guingand D, Hocking JS, Morton AN, Garland SM, Fehler G, Morrow A, Walker S, Vodstrcil LA, Fairley CK: Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. PLoS One 2012, 7:e34540.
• [21]Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, Kuzevska I, Fairley CK: High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006, 193:1478-86.
• [22]Chen JY, Tian H, Beigi RH: Treatment considerations for bacterial vaginosis and the risk of recurrence. J Womens Health (Larchmt) 2009, 18:1997-2004.
• [23]Larsson PG, Brandsborg E, Forsum U, Pendharkar S, Andersen KK, Nasic S, Hammarström L, Marcotte H: Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Infect Dis 2011, 11:223. BioMed Central Full Text
• [24]McClelland RS, Richardson BA, Graham SM, Masese LN, Gitau R, Lavreys L, Mandaliya K, Jaoko W, Baeten JM, Ndinya-Achola JO: A prospective study of risk factors for bacterial vaginosis in HIV-1-seronegative African women. Sex Transm Dis 2008, 35:617-23.
• [25]Balkus JE, Jaoko W, Mandaliya K, Richardson BA, Masese L, Gitau R, Kiarie J, Marrazzo J, Farquhar C, McClelland RS: The posttrial effect of oral periodic presumptive treatment for vaginal infections on the incidence of bacterial vaginosis and Lactobacillus colonization. Sex Transm Dis 2012, 39:361-5.
• [26]Schwebke JR, Desmond RA: A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis 2007, 44:213-9.
• [27]Klatt TE, Cole DC, Eastwood DC, Barnabei VM: Factors associated with recurrent bacterial vaginosis. J Reprod Med 2010, 55:55-61.
• [28]Smart S, Singal A, Mindel A: Social and sexual risk factors for bacterial vaginosis. Sex Transm Infect 2004, 80:58-62.
• [29]Thulkar J, Kriplani A, Agarwal N, Vishnubhatla S: Aetiology & risk factors of recurrent vaginitis & its association with various contraceptive methods. Indian J Med Res 2010, 131:83-7.
• [30]Yotebieng M, Turner AN, Hoke TH, Van Damme K, Rasolofomanana JR, Behets F: Effect of consistent condom use on 6-month prevalence of bacterial vaginosis varies by baseline BV status. Trop Med Int Health 2009, 14:480-6.
• [31]Myer L, Kuhn L, Denny L, Wright TC Jr: Recurrence of symptomatic bacterial vaginosis 12 months after oral metronidazole therapy in HIV-positive and -negative women. J Infect Dis 2006, 194:1797-9.
• [32]Brotman RM, Erbelding EJ, Jamshidi RM, Klebanoff MA, Zenilman JM, Ghanem KG: Findings associated with recurrence of bacterial vaginosis among adolescents attending sexually transmitted diseases clinics. J Pediatr Adolesc Gynecol 2007, 20:225-31.
• [33]Hay PE, Ugwumadu A, Chowns J: Sex, thrush and bacterial vaginosis. Int J STD AIDS 1997, 8:603-8.
• [34]Zabor EC, Klebanoff M, Yu K, Zhang J, Nansel T, Andrews W, Schwebke J, Jeffcoat M: Association between periodontal disease, bacterial vaginosis, and sexual risk behaviours. J Clin Periodontol 2010, 37:888-93.
• [35]Marrazzo JM, Fiedler TL, Srinivasan S, Thomas KK, Liu C, Ko D, Xie H, Saracino M, Fredricks DN: Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis 2012, 205:1580-8.
• [36]Schwebke JR, Richey CM, Weiss HL: Correlation of behaviors with microbiological changes in vaginal flora. J Infect Dis 1999, 180:1632-6.
• [37]Cherpes TL, Hillier SL, Meyn LA, Busch JL, Krohn MA: A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. Sex Transm Dis 2008, 35:78-83.
• [38]Larsson PG: Treatment of bacterial vaginosis. Int J STD AIDS 1992, 3:239-47.